Related Experiment Video

Updated: Jun 27, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.8K

Chitinase dysregulation predicts disease aggressiveness in ALS: Insights from the D50 progression model

Nayana Gaur1,2, Robert Steinbach2, Mario Plaas3

  • 1Laboratory Animal Center, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia nayana.gaur@ut.ee.

Journal of Neurology, Neurosurgery, and Psychiatry
|April 19, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
ALSCSFMOTOR NEURON DISEASENEUROMUSCULAR

More Related Videos

Measurement of Chitinase Activity in Biological Samples
03:32

Measurement of Chitinase Activity in Biological Samples

Published on: August 22, 2019

10.3K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Related Experiment Videos

Last Updated: Jun 27, 2026

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.8K
Measurement of Chitinase Activity in Biological Samples
03:32

Measurement of Chitinase Activity in Biological Samples

Published on: August 22, 2019

10.3K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.7K

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Articles linked to this work by shared authors, journal, and citation graph.

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Neurology·2026

Short-term ambient temperature increases are associated with higher mortality in amyotrophic lateral sclerosis: a case-crossover study of weather conditions.

Frontiers in aging neuroscience·2026

Plasma cardiac troponin T complements neurofilament light chain by reflecting disease phase and phenotypic variation in amyotrophic lateral sclerosis.

Journal of neurology·2026

Troponin T and Neurofilament Light Chain Levels as Complementary Biomarkers of Disease Accumulation and Aggressiveness in Amyotrophic Lateral Sclerosis.

Annals of clinical and translational neurology·2026

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026

Quantification of amyotrophic lateral sclerosis (ALS) disease accumulation with T1-weighted high-resolution magnetic resonance imaging: validation in an independent cohort.

Journal of neurology·2026

Prevalence, clinical characteristics and treatment response of tremor in chronic inflammatory demyelinating polyneuropathy.

Journal of neurology, neurosurgery, and psychiatry·2026

Whole-body quantitative muscle MRI in myotonic dystrophy type 2: a sensitive tool for pattern recognition, disease stratification and objective assessment of clinical severity.

Journal of neurology, neurosurgery, and psychiatry·2026

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Journal of neurology, neurosurgery, and psychiatry·2026

Balancing Benefits and Risks: Long-term Use of Daily versus Intermittent Corticosteroids in Duchenne Muscular Dystrophy.

Journal of neurology, neurosurgery, and psychiatry·2026

Epilepsy and education: a nationwide cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal of neurology, neurosurgery, and psychiatry·2026

CRISPR-Cas9‑based lipid nanocarriers for advanced therapy of urinary bladder cancer.

Nanomedicine (London, England)·2026

The experiences and satisfaction of patients in outpatient cancer clinics: A scoping review.

Journal of psychosocial oncology·2026

Recurrent oral ulceration after CD19 CAR T-cell therapy defines a delayed mucosal inflammatory phenotype.

Haematologica·2026

Effect of blueberry consumption on regulatory lymphocyte phenotypes and NK cell functional activity in middle-aged and older adults with overweight or obesity: a randomized controlled trial.

Frontiers in immunology·2026

Impact of acute stress on gastric interstitial cells of Cajal disorder.

Frontiers in cell and developmental biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us